IDT Australia Limited
ABN 66 006 522 970
45 Wadhurst Drive
Boronia, Victoria 3155, Australia
T +61 3 9801 8888
W www.idtaus.com.au

ASX ANNOUNCEMENT
20th August 2026

Significant Turnaround in FY26 Earnings and Projected Positive EBITDA for FY27

Highlights:

- **Improved operating leverage and profitability with FY26 EBITDA up 85%** as revenue from 3 verticals increased 16.5% to $16.8M under IDT's strategic reset.
- **IDT expected to report a positive EBITDA in FY27** on strong outlook underpinned by a growing global client base and increasing demand for its specialist CDMO capabilities.
- **Three-year $50M revenue target** supported by expansion of existing local & international strategic clients, customer acquisitions and investments to upgrade capabilities.
- **New $7M capital investment** (debt funded via existing facility) in a new sterile line and upgrade of solid oral capabilities to bolster IDT's competitive edge and pricing power.

IDT Australia Limited (ASX: IDT) (**IDT** or the **Company**) is pleased to announce significantly improved results for the financial year 2026 (**FY26**) and is on track to deliver positive operating earnings in the current financial year.

This outcome is driven by IDT's strategic reset with earnings before interest, tax, depreciation and amortisation (**EBITDA**) improving 85% year-on-year (**YoY**) to -$922K and ordinary revenue from IDT's three core verticals increasing 16.5% YoY to $16.8 million.

FY26 Performance Breakdown

	FY25	FY26
Revenue from 3 verticals	**$14.4M**	**$16.8M**
Composition:		
API	29.1%	32.3%
Specialty Orals	24.9%	32.5%
Advanced Therapies	45.9%	35.2%
Disbursements/Other	$5.4M	$3.6M
Total Revenue	$19.8M	$20.4M
EBITDA	**-$6.3M**	**-$0.9M**

Strong Rise in Earnings Highlighting IDT's Operating Leverage



About IDT
IDT (ASX:IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.

Strong local and international demand for IDT's agile, end-to-end drug manufacturing services, combined with a $0.5 million uplift to the cost savings target (now $2.5 million), contributed to the significantly reduced earnings loss in FY26, leaving IDT with $9.7 million in total funds ($2.6 million in cash and $7.1 million in unused available debt) to fund growth.

The decline in disbursement and other revenue to $3.6 million (FY25: $5.4 million) was expected and reflects the strategic decision to deprioritise narrow margin, pass through work. As a result, total revenue for the period was $20.4 million, or 3.1% ahead of the previous year, and net profit after tax was -$2.7 million, a 66.3% improvement over FY25.

Performance of Verticals

One of the key objectives of the strategic realignment is to prioritise profitability and to better capitalise on the operating leverage potential of the business.

Part of this strategy is to increase the focus on the Active Pharmaceutical Ingredient (**API**) Manufacturing business whilst still strategically engaging with clients on our other capabilities. This vertical posted a 29% YoY increase to its FY26 revenue to $5.4 million.

The API business focuses on small molecule API manufacturing, dealing with complex and high-potency chemistry. This is the legacy business and a core competency of IDT, and work from this vertical can often lead to contracts for its other two verticals.

Meanwhile, the Solid Oral Manufacturing vertical recorded a 52% YoY jump in full year revenue to $5.5 million. This business is successfully capitalising on opportunities in radiopharmaceuticals as it continues to service the demand for medicinal cannabis and psychedelic drugs.

The Sterile Manufacturing (Advanced Therapies) vertical delivered full year revenue of $5.9 million, a 11% YoY decline. This largely reflects the timing of contracts and the outlook for this business is very strong.

Based on IDT's current pipeline of opportunities and growing global demand for mRNA drugs, the Company expects the Sterile Manufacturing vertical to be a key growth driver for the group.

Operational Momentum and Positive Outlook

IDT enters this financial year with strong commercial momentum with the Company expecting to deliver a positive EBITDA in FY27, backed by a growing global client base and increasing demand for its specialist CDMO capabilities.

The Company's forward outlook is underpinned by its **three-year target to achieve $50 million in revenue by FY29**, supported by:

- Expansion of existing strategic accounts across Australia, the US, Europe, and APAC.
- Investments in a new sterile line and upgrade of solid oral capabilities to strengthen IDT's global leadership and competitive advantage (details below).

- New customer acquisition initiatives targeting high-growth biotech clusters.
- Increased market visibility through targeted conferences and in-market engagement.

High-Tech Manufacturing Investment Supporting Growth

IDT approved a $7 million capital investment program to significantly upgrade and expand its sterile and solid oral dose manufacturing capabilities.

This program, which will be funded entirely from IDT's existing debt facilities, includes the acquisition of world-leading high-tech pharmaceutical manufacturing equipment, enabling IDT to pursue high-value opportunities in markets with strong growing demand.

The new investment will add to our current capabilities of in manufacturing sterile pre-filled vials and enable IDT to additionally produce sterile pre-filled syringes and cartridges. Attracting new commercial scale opportunities for antibody drug conjugates (ADCs), biologics, biosimilars, mRNA vaccines, and speciality injectables.

Additionally, IDT will upgrade its solid oral equipment to strengthen its tablet press, coating, and bottle line capabilities. This expanded throughput will enable IDT to compete for a wider range of oral solid dose manufacturing contracts, including complex modified-release and fixed-dose combination products.

Industry Recognition

IDT Australia was honoured to be awarded the Asia-Pacific RNA Excellence Awards 2026 in Singapore. The Company received:

- Overall RNA Manufacturing Excellence Award
- Best Emerging RNA CDMO Award

These awards recognise the expertise, innovation, and dedication of IDT's team in advancing RNA research, development, and manufacturing. Together with global clients and partners, IDT is helping shape the future of RNA therapeutics by delivering high-quality manufacturing solutions that accelerate innovation and improve patient outcomes.

Mark Simari, the Executive Chair of IDT Australia, said:

"FY26 marks a turning point for IDT. Our financial performance has strengthened materially, we are tracking towards positive operating earnings this financial year, and our investment in advanced manufacturing capability positions us for the next phase of growth.

"Further, the recognition we received at the Asia-Pacific RNA Excellence Awards reflects the calibre of our team and the trust placed in us by global innovators. With a clear pathway toward our $50 million revenue target by FY29, IDT is exceptionally well-placed to capture the growing demand for specialist CDMO services across Australia and internationally."

Ends…. /

About IDT
IDT (ASX:IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.

IDT Australia Limited
ABN 66 006 522 970
45 Wadhurst Drive
Boronia, Victoria 3155, Australia
T +61 3 9801 8888
W www.idtaus.com.au

Authorised by the Board of Directors of IDT Australia Limited.

For investor and media enquiries, please contact:
Brendon Lau
E: brendon@vantagepointpartners.com.au
M: +61 409 341 613

Forward-looking statements

This announcement contains or may contain forward-looking statements that are based on IDT Australia's beliefs, assumptions, and expectations and on information currently available to IDT Australia.

All statements that address operating performance, events, or developments that IDT Australia or its directors expect or anticipate will occur in the future are forward-looking statements, including, without limitation, statements as to the expectations of IDT Australia or the market it operates in.

IDT Australia believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. IDT Australia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. No assurance or guarantee is, or should be taken to be, given in relation to, and no reliance should be placed on, the future business performance or results of IDT Australia or the likelihood that the current assumptions, estimates or outcomes will be achieved. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.